Zobrazeno 1 - 10
of 294
pro vyhledávání: '"van Bodegraven, A. A."'
Autor:
A Rezazadeh Ardabili, D van Esser, D Wintjens, M Cilissen, D Deben, Z Mujagic, F Russ, L Stassen, A van Bodegraven, D Wong, B Winkens, D Jonkers, M Romberg-Camps, M Pierik
Publikováno v:
Journal of Crohn's and Colitis. 17:i631-i634
Background Immunomodulators and biologicals are essential in current IBD management, but are associated with increased risk of infections. Considering the growing number of treatment options, the benefit-risk balance of drugs is becoming increasingly
Autor:
Melek Simsek, Femke Schepers, Sigal Kaplan, Dirk van Asseldonk, Petra van Boeckel, Paul Boekema, Gerard Dijkstra, Herma Fidder, Ingrid Gisbertz, Frank Hoentjen, Bindia Jharap, Frank Kubben, Marleen de Leest, Maarten Meijssen, Ana Petrak, Else van de Poel, Maurice Russel, Adriaan A van Bodegraven, Chris J J Mulder, Nanne de Boer
Publikováno v:
Simsek, M, Schepers, F, Kaplan, S, van Asseldonk, D, van Boeckel, P, Boekema, P, Dijkstra, G, Fidder, H, Gisbertz, I, Hoentjen, F, Jharap, B, Kubben, F, de Leest, M, Meijssen, M, Petrak, A, van de Poel, E, Russel, M, van Bodegraven, A A, Mulder, C J J & de Boer, N 2023, ' Thioguanine is Effective as Maintenance Therapy for Inflammatory Bowel Disease : A Prospective Multicentre Registry Study ', Journal of Crohn's and Colitis, vol. 17, no. 6, pp. 933-942 . https://doi.org/10.1093/ecco-jcc/jjad013
Journal of Crohn's and Colitis, 17, 6, pp. 933-942
Journal of Crohn's and Colitis, 17, 6, pp. 933-942
Background and AimsThioguanine is a well-tolerated and effective therapy for inflammatory bowel disease [IBD] patients. Prospective effectiveness data are needed to substantiate the role of thioguanine as a maintenance therapy for IBD.MethodsIBD pati
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::33731b5f29a889c5b8b0e40df5586d7c
https://research.vumc.nl/en/publications/e785eb96-f4bc-448d-ab45-a6bfaedc15c3
https://research.vumc.nl/en/publications/e785eb96-f4bc-448d-ab45-a6bfaedc15c3
Effectiveness and safety of tofacitinib for ulcerative colitis: two‐year results of the ICC Registry
Autor:
Tessa Straatmijer, Fiona D. M. van Schaik, Alexander G. L. Bodelier, Marijn Visschedijk, Annemarie C. de Vries, Cyriel Y. Ponsioen, Marieke Pierik, Ad A. van Bodegraven, Rachel L. West, Nanne K. H. de Boer, Nidhi Srivastava, Tessa E. H. Romkens, Jildou Hoekstra, Bas Oldenburg, Gerard Dijkstra, Janneke C. van der Woude, Mark Löwenberg, Zlatan Mujagic, Vince B. C. Biemans, Andrea E. van der Meulen‐de Jong, Marjolijn Duijvestein
Publikováno v:
Alimentary Pharmacology & Therapeutics, 57, 1, pp. 117-126
Alimentary Pharmacology & Therapeutics, 57, 117-126
Alimentary Pharmacology and Therapeutics, 57(1), 117-126
Alimentary Pharmacology and Therapeutics, 57(1), 117-126. Wiley-Blackwell
Straatmijer, T, van Schaik, F D M, Bodelier, A G L, Visschedijk, M, de Vries, A C, Ponsioen, C Y, Pierik, M, van Bodegraven, A A, West, R L, de Boer, N K H, Srivastava, N, Romkens, T E H, Hoekstra, J, Oldenburg, B, Dijkstra, G, van der Woude, J C, Löwenberg, M, Mujagic, Z, Biemans, V B C, van der Meulen-de Jong, A E & Duijvestein, M 2023, ' Effectiveness and safety of tofacitinib for ulcerative colitis : two-year results of the ICC Registry ', Alimentary Pharmacology and Therapeutics, vol. 57, no. 1, pp. 117-126 . https://doi.org/10.1111/apt.17248
Alimentary Pharmacology & Therapeutics, 57(1), 117-126. Wiley
Alimentary Pharmacology and Therapeutics, 57(1), 117-126. Wiley-Blackwell Publishing Ltd
Alimentary Pharmacology and Therapeutics, 57(1), 117-126. WILEY
Alimentary Pharmacology & Therapeutics, 57, 117-126
Alimentary Pharmacology and Therapeutics, 57(1), 117-126
Alimentary Pharmacology and Therapeutics, 57(1), 117-126. Wiley-Blackwell
Straatmijer, T, van Schaik, F D M, Bodelier, A G L, Visschedijk, M, de Vries, A C, Ponsioen, C Y, Pierik, M, van Bodegraven, A A, West, R L, de Boer, N K H, Srivastava, N, Romkens, T E H, Hoekstra, J, Oldenburg, B, Dijkstra, G, van der Woude, J C, Löwenberg, M, Mujagic, Z, Biemans, V B C, van der Meulen-de Jong, A E & Duijvestein, M 2023, ' Effectiveness and safety of tofacitinib for ulcerative colitis : two-year results of the ICC Registry ', Alimentary Pharmacology and Therapeutics, vol. 57, no. 1, pp. 117-126 . https://doi.org/10.1111/apt.17248
Alimentary Pharmacology & Therapeutics, 57(1), 117-126. Wiley
Alimentary Pharmacology and Therapeutics, 57(1), 117-126. Wiley-Blackwell Publishing Ltd
Alimentary Pharmacology and Therapeutics, 57(1), 117-126. WILEY
Contains fulltext : 290620.pdf (Publisher’s version ) (Open Access) BACKGROUND: Tofacitinib is an oral Janus kinase (JAK) inhibitor and is registered for the treatment of ulcerative colitis (UC). The effectiveness of tofacitinib has been evaluated
Autor:
K Demers, A Rezazadeh Ardabili, B C Bongers, M J L Romberg-Camps, A A van Bodegraven, D M A E Jonkers, M J Pierik, L P S Stassen
Publikováno v:
Journal of Crohn's and Colitis. 17:i362-i364
Background Cardiorespiratory fitness (CRF) as a potential predictor of disease outcome in Inflammatory Bowel Disease (IBD) is understudied, as are risk factors for impaired CRF. Lifestyle interventions focusing on improving CRF may aid in enhancing s
Autor:
Eduard A. van Bodegraven, Michiel F.G. Francken, Koen C.H.A. Verkoulen, M. Abu Hilal, Marcel G.W. Dijkgraaf, Marc G. Besselink
Publikováno v:
HPB.
Publikováno v:
Journal of Crohn's and Colitis.
Introduction The traditional long-term treatment goal of Crohn’s disease(CD) is maintenance of corticosteroid free clinical remission. Additional treatment targets, such as biochemical, endoscopic, and patient reported remission, are advocated. The
Autor:
Mark Löwenberg, Adriaan Volkers, Sara van Gennep, Aart Mookhoek, Nahid Montazeri, Esmé Clasquin, Marjolijn Duijvestein, Adriaan van Bodegraven, Svend Rietdijk, Jeroen Jansen, Dirk van Asseldonk, Esmerij van der Zanden, Marcel Dijkgraaf, Rachel West, Nanne de Boer, Geert D’Haens
Publikováno v:
Journal of Crohn's and Colitis, 17, 7, pp. 1055-1065
Background and Aims Scepticism about the efficacy of thiopurines for ulcerative colitis [UC] is rising. This study aimed to evaluate mercaptopurine treatment for UC. Methods In this prospective, randomized, double-blind, placebo-controlled trial, pat
Autor:
Ashkan Rezazadeh Ardabili, Dirk van Esser, Dion Wintjens, Mia Cilissen, Debbie Deben, Zlatan Mujagic, Fritzi Russ, Laurents Stassen, Adriaan A Van Bodegraven, Dennis Wong, Bjorn Winkens, Daisy Jonkers, Mariëlle Romberg-Camps, Marie J Pierik
Publikováno v:
Journal of Crohn's & Colitis.
Background Immunomodulators and biologics are cornerstones in the management of inflammatory bowel disease [IBD], but are associated with increased risk of infections. Post-marketing surveillance registries are pivotal to assess this risk, yet mainly
Autor:
Reinier C A van Linschoten, Fenna M Jansen, Renske W M Pauwels, Lisa J T Smits, Femke Atsma, Wietske Kievit, Dirk J de Jong, Annemarie C de Vries, Paul J Boekema, Rachel L West, Alexander G L Bodelier, Ingrid A M Gisbertz, Frank H J Wolfhagen, Tessa E H Römkens, Maurice W M D Lutgens, Adriaan A van Bodegraven, Bas Oldenburg, Marieke J Pierik, Maurice G V M Russel, Nanne K de Boer, Rosalie C Mallant-Hent, Pieter C J ter Borg, Andrea E van der Meulen-de Jong, Jeroen M Jansen, Sita V Jansen, Adrianus C I T L Tan, C Janneke van der Woude, Frank Hoentjen, Desirée van Noord, Jildou Hoekstra, Johannes T. Kamphuis, Moniek H.P. Gorter, Aura A.J. van Esch
Publikováno v:
Lancet Gastroenterology & Hepatology, 8, 4, pp. 343-355
Lancet Gastroenterology & Hepatology, 8, 343-355
The Lancet Gastroenterology and Hepatology, 8(4), 343-355. Elsevier Ltd
LADI study group and the Dutch Initiative on Crohn and Colitis 2023, ' Increased versus conventional adalimumab dose interval for patients with Crohn's disease in stable remission (LADI) : a pragmatic, open-label, non-inferiority, randomised controlled trial ', The Lancet Gastroenterology and Hepatology, vol. 8, no. 4, pp. 343-355 . https://doi.org/10.1016/S2468-1253(22)00434-4
The Lancet Gastroenterology and Hepatology, 8(4), 343-355. Elsevier Ltd.
Lancet Gastroenterology & Hepatology, 8, 343-355
The Lancet Gastroenterology and Hepatology, 8(4), 343-355. Elsevier Ltd
LADI study group and the Dutch Initiative on Crohn and Colitis 2023, ' Increased versus conventional adalimumab dose interval for patients with Crohn's disease in stable remission (LADI) : a pragmatic, open-label, non-inferiority, randomised controlled trial ', The Lancet Gastroenterology and Hepatology, vol. 8, no. 4, pp. 343-355 . https://doi.org/10.1016/S2468-1253(22)00434-4
The Lancet Gastroenterology and Hepatology, 8(4), 343-355. Elsevier Ltd.
Item does not contain fulltext BACKGROUND: Despite its effectiveness in treating Crohn's disease, adalimumab is associated with an increased risk of infections and high health-care costs. We aimed to assess clinical outcomes of increased adalimumab d
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1d4a13f67ca392c8811058105e50cf3a
https://repository.ubn.ru.nl/handle/2066/293716
https://repository.ubn.ru.nl/handle/2066/293716
Autor:
Tessa Straatmijer, Vince B.C. Biemans, Marijn Visschedijk, Frank Hoentjen, Annemarie de Vries, Adriaan A. van Bodegraven, Alexander Bodelier, Nanne K.H. de Boer, Gerard Dijkstra, Noortje Festen, Carmen Horjus, Jeroen M. Jansen, Bindia Jharap, Wout Mares, Fiona D.M. van Schaik, Cyriel Ponsioen, Tessa Romkens, Nidhi Srivastava, Michael M.P. J.A. van der Voorn, Rachel West, Janneke van der Woude, Marije D.J. Wolvers, Marieke Pierik, Andrea E. van der Meulen-de Jong, Marjolijn Duijvestein, Malena Schlotter, Martine van Workum, Dirk de Jong, Willemijn van Dop, S. van der Marel, Hayat El Ghabzouri, Kamila Talhaoui, Bas Oldenburg, Nynke Boontje, Herma Fidder, Meike Hirdes, Rob H. Creemers, J. Hoekstra, Jael Smid, Zlatan Mujagic, Marthe François-Verweij, Toos Schakel- van den Berge, Jeroen Maljaars, Rosaline Theeuwen, Denise van den Berg, Suzanne Gerretsen, Xenia Yocarini, Geert D’Haens, Mark Lowenberg, Joep Grootjans, Krisztina Gecse, Gerd Bouma, Petra Waaijenberg, Bart Muskens
Publikováno v:
Clinical Gastroenterology and Hepatology, 21(1), 182-191.e2. ELSEVIER SCIENCE INC
Clinical Gastroenterology and Hepatology, 21, 1, pp. 182-191.e2
Clinical Gastroenterology and Hepatology, 21(1), 182-191.e2. W.B. Saunders Ltd
Clinical Gastroenterology and Hepatology, 21, 182-191.e2
Clinical gastroenterology and hepatology. Elsevier Science
Clinical gastroenterology and hepatology, 21(1), 182-191.e2. W.B. Saunders Ltd
Initiative on Crohn and Colitis 2023, ' Superior Effectiveness of Tofacitinib Compared to Vedolizumab in Anti-TNF-experienced Ulcerative Colitis Patients : A Nationwide Dutch Registry Study ', Clinical Gastroenterology and Hepatology, vol. 21, no. 1, pp. 182-191.e2 . https://doi.org/10.1016/j.cgh.2022.04.038
Clinical Gastroenterology and Hepatology, 21(1), 182-191.e2. W.B. Saunders
Clinical Gastroenterology and Hepatology, 21, 1, pp. 182-191.e2
Clinical Gastroenterology and Hepatology, 21(1), 182-191.e2. W.B. Saunders Ltd
Clinical Gastroenterology and Hepatology, 21, 182-191.e2
Clinical gastroenterology and hepatology. Elsevier Science
Clinical gastroenterology and hepatology, 21(1), 182-191.e2. W.B. Saunders Ltd
Initiative on Crohn and Colitis 2023, ' Superior Effectiveness of Tofacitinib Compared to Vedolizumab in Anti-TNF-experienced Ulcerative Colitis Patients : A Nationwide Dutch Registry Study ', Clinical Gastroenterology and Hepatology, vol. 21, no. 1, pp. 182-191.e2 . https://doi.org/10.1016/j.cgh.2022.04.038
Clinical Gastroenterology and Hepatology, 21(1), 182-191.e2. W.B. Saunders
Background & Aims: Clinicians face difficulty in when and in what order to position biologics and Janus kinase inhibitors in patients with anti-tumor necrosis factor-alpha (TNF) refractory ulcerative colitis (UC). We aimed to compare the effectivenes
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::16c5fd40e67e975df5ce34fd01d6aa67
https://research.rug.nl/en/publications/4d7e144b-6332-47f9-9cee-542a2092238d
https://research.rug.nl/en/publications/4d7e144b-6332-47f9-9cee-542a2092238d